Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Radiotherapy 106Cyclophosphamide 97Cisplatin 75Carboplatin 66Fluorouracil 64Etoposide 61Doxorubicin 60Chemotherapy, Adjuvant 60Vincristine 56Peripheral Blood Stem Cell Transplantation 48Filgrastim 47Paclitaxel 46Gemcitabine 44Cytarabine 41Neoadjuvant Therapy 40Leucovorin 40Docetaxel 35Melphalan 31Oxaliplatin 29Methotrexate 29Ifosfamide 25Gene Expression Profiling 25Amplified Fragment Length Polymorphism Analysis 24Immunohistochemistry 23Dexamethasone 22Irinotecan 21aldesleukin 20Prednisolone 20Interferon-alpha 20Tamoxifen 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NIH × Rosiglitazone × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡